Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246971 | 1.00 | UCHL1 (0.49) | UCHL1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8249835 | 0.92 | UCHL1 (0.49) | UCHL1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4406868 | 0.92 | UCHL1 (0.49) | UCHL1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL13123350 | 0.92 | KDM4E (0.48) | UCHL1SMN1; SMN2P2RX3MCL1TACR3 | |
| SCHEMBL8275065 | 0.92 | KDM4E (0.48) | UCHL1SMN1; SMN2P2RX3MCL1TACR3 | |
| SCHEMBL8248157 | 0.91 | UCHL1 (0.47) | UCHL1ACACBP2RX3MCL1 | |
| SCHEMBL8253556 | 0.89 | UCHL1 (0.45) | UCHL1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8213225 | 0.89 | UCHL1 (0.45) | UCHL1ACACBLMNAHPGDSMN1; SMN2 | |
| SCHEMBL12934484 | 0.89 | UCHL1 (0.45) | UCHL1ACACBP2RX3MCL1 | |
| SCHEMBL8213890 | 0.87 | UCHL1 (0.43) | UCHL1ACACBSMN1; SMN2P2RX3MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
| EP-1915382-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007016476-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PRSS1 | UCHL1 665/4885HTR3E 1692/4885HTR3B 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.